Isr Med Assoc J
-
The use of proprotein convertase subtilisin/kexin type 9 monoclonal antibodies (PCSK9 mAbs) is emerging for lowering low-density lipoprotein cholesterol (LDL-C). However, real-world data is lacking for their use among elderly patients. ⋯ PCSK9 mAbs have similar effects and are well tolerated among elderly patients as in younger patients.